Racial Differences in Clinical Phenotype and Hospitalization of Blastomycosis Patients.

Background: Dimorphic fungal infections, such as blastomycosis, cause significant morbidity and mortality. Historically, blastomycosis studies have focused on non-Hispanic whites, which limits our understanding of the clinical presentation and outcomes for patients of other races and ethnicities. We evaluated whether clinical presentation and disease severity varied across racial and ethnic groups.

Methods: Blastomycosis patients were identified from Marshfield Clinic Health System and data were abstracted from electronic medical records. genotyping was performed for cases with available isolates. Bivariate analyses (χ  tests/analysis of variance) assessed associations of race and/or ethnicity, spp, and hospitalization status with demographics and clinical presentation. Multivariable logistic regression was used to evaluate the association of race and/or ethnicity and hospitalization.

Results: In total, 477 patients were included. Age differences were observed across race and ethnicity categories ( < .0001). Non-Hispanic whites were oldest (median, 48 years; interquartile range [IQR], 31-62) and Asians were youngest (26 years; IQR, 19-41). Non-Hispanic whites (55%) and African Americans (52%) had underlying medical conditions more frequently than Hispanic whites (27%) and Asians (29%). Odds of hospitalization were 2 to 3 times higher for Hispanic whites (adjusted odds ratio [aOR], 2.9; 95% confidence interval [CI], 1.2-1.7), American Indian or Alaska Native (AIAN) (aOR, 2.4; 95% CI, 1.0-5.5), and Asian (aOR, 1.9; 95% CI, 1.0-3.6) patients compared with non-Hispanic white patients. Ninety percent of infections occurred in non-Hispanic whites, whereas blastomycosis in Hispanic whites, AIAN, and Asian patients was frequently caused by ( < .0001).

Conclusions: Hispanic whites, AIAN, and Asian blastomycosis patients were younger and healthier but more frequently hospitalized. Patients in these racial and ethnic groups may need more aggressive treatment and closer therapeutic monitoring.